ANCHIANO THERAPEUTICS LTD.
February 10, 2021
VIA EDGAR
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Acceleration Request of Anchiano Therapeutics Ltd. |
Registration Statement on Form S-4, as amended
Filed on January 13, 2021 (File No. 333-252070)
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Anchiano Therapeutics Ltd. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-252070), as amended (the “Registration Statement”), so that it may become effective at 1:30 p.m. Eastern Time on February 12, 2021, or as soon as possible thereafter.
The Company hereby authorizes Joshua A. Kaufman, Esq. of Cooley LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Attorney Kaufman at (212) 479-6495 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Attorney Kaufman.
| Very truly yours, | |
| ANCHIANO THERAPEUTICS LTD. | |
| /s/ Neil Cohen | |
| Neil Cohen | |
| Interim Chief Executive Officer |
cc:
Michal Berkner, Esq.
Joshua A. Kaufman, Esq.
Cooley LLP
Aaron M. Lampert, Esq.
Goldfarb Seligman & Co.
Adi Mor, Chief Executive Officer
Chemomab Ltd.
Shachar Hadar, Esq.
Ronen Bezalel, Esq.
David S. Glatt, Esq.
Jonathan M. Nathan, Esq.
Meitar | Law Offices
